These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31991082)

  • 1. Enhanced in Vivo Blood-Brain Barrier Penetration by Circular Tau-Transferrin Receptor Bifunctional Aptamer for Tauopathy Therapy.
    Li X; Yang Y; Zhao H; Zhu T; Yang Z; Xu H; Fu Y; Lin F; Pan X; Li L; Cui C; Hong M; Yang L; Wang KK; Tan W
    J Am Chem Soc; 2020 Feb; 142(8):3862-3872. PubMed ID: 31991082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases.
    Macdonald J; Henri J; Goodman L; Xiang D; Duan W; Shigdar S
    ACS Chem Neurosci; 2017 Apr; 8(4):777-784. PubMed ID: 28010059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
    Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
    J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transferrin Aptamers Increase the
    Kusmierz CD; Callmann CE; Kudruk S; Distler ME; Mirkin CA
    Bioconjug Chem; 2022 Oct; 33(10):1803-1810. PubMed ID: 36194889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core.
    Clark AJ; Davis ME
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12486-91. PubMed ID: 26392563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor.
    Wiley DT; Webster P; Gale A; Davis ME
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8662-7. PubMed ID: 23650374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Immortalized Cell-Based Blood-Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules.
    Kitamura K; Okamoto A; Morio H; Isogai R; Ito R; Yamaura Y; Izumi S; Komori T; Ito S; Ohtsuki S; Akita H; Furihata T
    Mol Pharm; 2022 Aug; 19(8):2754-2764. PubMed ID: 35766901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology.
    Bourassa P; Alata W; Tremblay C; Paris-Robidas S; Calon F
    Mol Pharm; 2019 Feb; 16(2):583-594. PubMed ID: 30609376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
    Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
    Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain.
    Sato S; Liu S; Goto A; Yoneyama T; Okita K; Yamamoto S; Hirabayashi H; Iwasaki S; Kusuhara H
    J Control Release; 2023 May; 357():379-393. PubMed ID: 37031741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells.
    Macdonald J; Denoyer D; Henri J; Jamieson A; Burvenich IJG; Pouliot N; Shigdar S
    Nucleic Acid Ther; 2020 Apr; 30(2):117-128. PubMed ID: 32027209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
    Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
    Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
    Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
    Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes.
    Johnsen KB; Moos T
    J Control Release; 2016 Jan; 222():32-46. PubMed ID: 26658072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
    Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
    J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
    Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
    Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau Proteins Cross the Blood-Brain Barrier.
    Banks WA; Kovac A; Majerova P; Bullock KM; Shi M; Zhang J
    J Alzheimers Dis; 2017; 55(1):411-419. PubMed ID: 27662303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.
    Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J
    Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy.
    Blair LJ; Frauen HD; Zhang B; Nordhues BA; Bijan S; Lin YC; Zamudio F; Hernandez LD; Sabbagh JJ; Selenica ML; Dickey CA
    Acta Neuropathol Commun; 2015 Jan; 3():8. PubMed ID: 25775028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.